Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Apr 27, 2021 5:25pm
127 Views
Post# 33079179

RE:RE:RE:RE:Mr. SPCEO

RE:RE:RE:RE:Mr. SPCEOI would be really shocked if the failure to sell the NASH opportunity to the NASH analysts had much to do with their not giving it enough of an effort. I believe they likely tried hard to get the job done. The issue is that this effort was clearly not effective. The oddity of how they got to general NASH is likely partly, if not fully, to blame for that lack of effectiveness. You know that you were skeptical of their ability to pull off getting the FDA to go along with the general NASH phase III, so I imagine those same concerns were shared by others. Once they jumped that hurdle, though, they gave it no time to sink into investors before pricing the OO at such low a low level.

As you point out, the long arduous process to get from HIV NASH to general NASH likely lost some people along the way, assumming anyone was paying any attention in the first place and I am not sure any were. The main problem is just an ineffective capital market's strategy and a poor effort to highlight the amazing Nachievements in NASH and cancer while allowing the failures in the commerecialization of Egrifta and Trogarzo to define the company to investors. 


qwerty22 wrote:

What do you think the impact of this very extended regulatory process has been? It's 2 years and we are still waiting for them to finalize the protocol never mind get the trial started.

I can't believe anybody believed it would take this long, including the company. This must have had some impact on selling the story. One thing you can say is they mostly didn't get ahead of the process (except maybe in the run up to the offering). Things could be even more worse if they'd got pumpy 12 to 18 months ago. 

This is not an unproblematic program in many ways. It needs clarification on the facts as much as it needs the story shopped around.

 

qwerty22 wrote:

 

The only real evidence we have is they tried to sell the NASH story to the legacy analysts and failed. That included some reasonably thoughtful guys like Ed Nash. How do you know they haven't been out trying to sell it to others and failing there as well? Do you know any people in your network that they've approached? Or people you might expect them to approach and didnt?

 

SPCEO1 wrote: Thanks for your kind words about my contribution here. Let's just see how things play out. Maybe we willl get more than worthless words from Wino's hoped for interaction with Paul and Dawn, assuming they actually talk. Time is of the essence on that and I hope we can get some feedback from Wino by the end of this week. 

As for how any of us vote, well, we can all vote as we please. I doubt we will all agree 100% with how we should vote whenever, and if, we hear something from Wino. Each person will need to consider the facts and make up their own mind. Since I may end up controlling the swings votes, I am open to any wisdom on this you and others want to share with me before I make my final selections. 

I am not as concerned as you are about management and board members intentionally treating sharehoders badly in any deal that may eventually be done. But we have all seen with the OO how underinvesting in public and investor relations led a very bad outcome and the board is  ultimately responsible for this failure. So, whether intentional or not, there is a risk of a bad outcome. Perhaps voting against a board member or two is the right way to send that message. Even if we are unsuccessful in removing any board member, the message will still have been sent. 

As you noted, I did encourage people not to forget the OO as time passes and especially when it came time to vote for the board. And I have not forgotten it. Voting against some or even all of this board can be justified based on how atrocious the OO was on every level. But I also do not want to completely disregard the many good things the board did for shareholders over the years. They really, really screwed up with the OO but they also really did some amazing things by getting us to phase III in general NASH and purchasing Katana. So, I want to be as fair as I can as I consider my options. I would not want my clients  judging me completely by the mistake owning TH has been for them and not look at all the other investments that we made that worked for them, so I am going to try to be even handed about this despitemy still lingering outrage at the OO.

The OO was actually just the symptom, not the problem. The problem was failing to build a  decent brand with investors over the years. The result is no one is paying any attention as the company gets Fast Track status in cancer or moves surprisingly into general NASH. Investors seem to be giving credit for magic mushrooms and a thousand other nonsensical things at the moment but are unwilling to give any credit to TH for its impressive achievements in NASH and cancer. It is hard to take and it is the result of mis-managing relations with all of thevarious  players in the capital markets. Our CEO has many good qualities but both he and the board seem to be lacking the needed experience and contacts required to build a good brand for TH's stock in the US.       
 

 

CreatingApe wrote: First of all thank you again for all your contributions here. But i have to say. Regardless if Mr. Wino leaves his call with management with a warm fuzzy feeling. It will just be words that they are saying. And their recent actions speak a lot louder than words. You say that you have not gone through the stages of grief yet and that none of us should ever forget that we were all thrown under the bus by the recent "dumpster fire" of a financing. But letting them all off the hook so easily after what just happened seems like you have forgotten your own advice, and are forgiving and forgetting very quickly. Long story short, i dont think it is so crazy or malicious for us to vote off a couple members of the board who literally have NO skin in the game and don't seem to be bringing anything to the table. While taking full bonuses at our expense. Their interests are not aligned with ours, that is clear. And i truly believe, that they have proven, if and when the time comes for Theratechnologies to be bought out. We will not receive even close to real value of our investments... while they will make off with the lions share. I DO feel that our new CEO is slowly implementing changes to the company that we all want and need. And i have faith in him. But why don't we help him and expedite that process of change a little bit. I see no reason not two vote off the two members of the board you suggested in an earlier post. Regardless of whether they whisper sweet nothings to wino or not. Assuming they even take his call... Being a friendly investor is one thing. But allowing ourselves to be taken advantage of is another. Maybe i am being dramatic. But that is my two cents. Thank you again for all of your contributions and expertise.

 

 




<< Previous
Bullboard Posts
Next >>